ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-OR078

Sex Differences in the Renal Hemodynamic Response to Angiotensin II Post-CPAP Therapy in Women and Men with Obstructive Sleep Apnea

Session Information

Category: Hypertension and CVD

  • 1403 Hypertension and CVD: Mechanisms


  • Nicholl, David Donald McTavish, University of Calgary, Calgary, Alberta, Canada
  • Hanly, Patrick, University of Calgary, Calgary, Alberta, Canada
  • Zalucky, Ann A., University of Calgary, Calgary, Alberta, Canada
  • Handley, George, Healthy Heart Sleep Company, Calgary, Alberta, Canada
  • Sola, Darlene Y., University of Calgary, Calgary, Alberta, Canada
  • Ahmed, Sofia B., University of Calgary, Calgary, Alberta, Canada

Women have slower loss of kidney function and chronic kidney disease (CKD) progression. The renin-angiotensin system (RAS) and the vascular effects of obstructive sleep apnea (OSA) differ by sex. OSA is associated with glomerular hypertension which can be reversed by continuous positive airway pressure (CPAP) therapy. We sought to determine whether sex differences exist in the effect of CPAP for OSA on renal hemodynamics and the renal RAS in humans.


Twenty-nine (10 female, 19 male; 49±2y) incident, otherwise healthy, OSA subjects (respiratory disturbance index [RDI]>15h-1) with nocturnal hypoxemia (SaO2<90% >12%/night) were studied in high-salt balance, a state of maximal RAS suppression, pre-CPAP and after 4 weeks of effective CPAP therapy (>4h/night). Renal plasma flow (RPF) and glomerular filtration rate (GFR) were measured by para-aminohippurate and inulin clearance technique at baseline and in response to Angiotensin II (AngII) challenge (3ng/kg/min x 30min, 6ng/kg/min x 30min), a marker of renal RAS activity, pre- and post-CPAP. The primary outcome was the effect of CPAP on the renal hemodynamic responses to AngII in women compared to men.


CPAP corrected OSA and nocturnal hypoxemia (RDI: 44±4 vs 4±1hr-1, p<0.001; duration SaO2<90%: 45±6 vs 7±2%, p<0.001). In women, CPAP was associated with a significant increase in RPF (626±22 vs 718±43 mL/min, p=0.007) but no change in GFR (108±2 vs 105±3 mL/min, p=0.8), whereas in men, CPAP use was not associated with changes in renal hemodynamics (RPF: 710±37 vs 756±38 mL/min, p=0.11; p=0.7 vs women; GFR: 124±8 vs 113±6 mL/min, p=0.085; p=0.5 vs women). Pre-CPAP, there was no difference in the RPF or GFR responses to AngII between women and men. Post-CPAP, there was a significantly greater renovasoconstrictive response to AngII in women (RPF: Δ30min: -100±27 vs -161±25 mL/min, p=0.007; Δ60min: -138±27 vs -206±32 mL/min, p=0.007), but not in men (RPF: Δ30min: -142±14 vs -154±19 mL/min, p=0.4; Δ60min: -168±23 vs -200±23 mL/min, p=0.053). Post-CPAP women had a larger initial reduction in GFR in response to AngII compared to men (Δ30min: -5±3 vs 0±2 mL/min, p=0.039; vs men).


CPAP therapy for OSA is associated with altered renal hemodynamics and downregulation of renal RAS activity in women but not in men.